FDA.reportPublic FDA data

0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]

RxCUI
2696267
RxNorm name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Display name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Full name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:20

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761298Pavbluaflibercept-ayyh351(k) InterchangeableRx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
c61062f3-80ec-4a20-8c28-46e468592a06PAVBLU 2 MG in 0.05 ML Prefilled Syringe [PSN] · 0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu] [SBD] · 0.05 ML Pavblu 40 MG/ML Prefilled Syringe [SY] · Pavblu 2 MG per 0.05 ML Prefilled Syringe [SY]49These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260510